IN8bio, Inc.
$1.5
▲
2.86%
2026-04-21 07:30:01
in8bio.com
NCM: INAB
Explore IN8bio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$14.77 M
Current Price
$1.5
52W High / Low
$5.82 / $1.17
Stock P/E
—
Book Value
$2.82
Dividend Yield
—
ROCE
-68.2%
ROE
-92.49%
Face Value
—
EPS
$-4.44
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
17
Beta
0.04
Debt / Equity
10.1
Current Ratio
8.82
Quick Ratio
8.82
Forward P/E
-0.92
Price / Sales
—
Enterprise Value
$-10.62 M
EV / EBITDA
0.59
EV / Revenue
—
Rating
Strong Buy
Target Price
$6.25
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | MacroGenics, Inc. | $3.48 | — | $228.17 M | — | -34.08% | -86.94% | $3.88 / $1.11 | $0.88 |
| 2. | IGC Pharma, Inc. | $0.32 | — | $31.52 M | — | -114.73% | -83.34% | $0.5 / $0.24 | $0.09 |
| 3. | Edesa Biotech, Inc. | $6.75 | — | $49.5 M | — | -57.24% | -96.39% | $9.37 / $0.72 | $0.56 |
| 4. | Alzamend Neuro, Inc. | $1.11 | — | $4.26 M | — | -113.32% | -2.5% | $8.22 / $0.84 | $0.57 |
| 5. | iBio, Inc. | $1.97 | — | $70.3 M | — | -108.92% | -70.22% | $3.82 / $0.56 | $1.88 |
| 6. | Moolec Science SA | $7.28 | — | $5.29 M | — | 11.2% | 344.24% | $157.05 / $3.07 | $0.7 |
| 7. | CervoMed Inc. | $3.97 | — | $36.76 M | — | -155.27% | -93.92% | $13.13 / $3.51 | $1.97 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -5.03 M | -3.97 M | -5.2 M | -5.66 M | -6.22 M | — |
| Net Profit | -4.94 M | -3.85 M | -5.09 M | -5.55 M | -6.16 M | — |
| EPS in Rs | -0.5 | -0.39 | -0.52 | -0.56 | -0.63 | -4.49 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -19.86 M | -29.6 M | -30.01 M | -28.52 M |
| Net Profit | -19.44 M | -30.44 M | -30.01 M | -28.52 M |
| EPS in Rs | -1.97 | -3.09 | -3.05 | -2.9 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 32.28 M | 20.94 M | 33.71 M | 33.04 M |
| Total Liabilities | 4.72 M | 6.47 M | 8.77 M | 10.31 M |
| Equity | 27.56 M | 14.48 M | 24.94 M | 22.73 M |
| Current Assets | 27.88 M | 12.58 M | 24.62 M | 22.23 M |
| Current Liabilities | 3.16 M | 3.08 M | 5.39 M | 5.82 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -12.71 M | -24.15 M | -23.34 M | -24.12 M |
| Investing CF | 0 M | -0.19 M | -0.6 M | -3.71 M |
| Financing CF | 28.64 M | 14.18 M | 27.04 M | 8.99 M |
| Free CF | -12.71 M | -24.34 M | -23.94 M | -27.83 M |
| Capex | — | -0.19 M | -0.6 M | -3.71 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -1.43% | -5.21% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-06-06 | 1:0.0333333 |